U.S. markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
95.98-1.80 (-1.84%)
At close: 4:00PM EDT
97.00 +1.02 (1.06%)
After hours: 04:53PM EDT

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court
Novato, CA 94949
United States
415 483 8800

Full Time Employees893

Key Executives

NameTitlePayExercisedYear Born
Dr. Emil D. Kakkis M.D., Ph.D.Pres, CEO & Director1.43MN/A1960
Ms. Mardi C. DierExec. VP & CFO216.35kN/A1964
Mr. John Richard Pinion IIChief Quality Operations Officer & Exec. VP of Translational Sciences747.2kN/A1966
Dr. Camille L. BedrosianChief Medical Officer & Exec. VP844.42kN/A1953
Mr. Erik HarrisExec. VP & Chief Commercial Officer793.86kN/A1970
Mr. Theodore A. HuizengaVP, Corp. Controller & Principal Accounting OfficerN/AN/A1971
Mr. Dennis Karl HuangChief Technical Operations Officer & Exec. VPN/AN/A1965
Ms. Danielle KeatleySr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Karah Herdman Parschauer J.D.Gen. Counsel & Exec. VPN/AN/A1978
Mr. Ernie W. MeyerChief HR Officer & Exec. VPN/AN/A1964
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Corporate Governance

Ultragenyx Pharmaceutical Inc.’s ISS Governance QualityScore as of June 1, 2021 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.